Why the study?
Pulmonary artery intimal sarcoma is a rare, aggressive malignancy with diagnostic challenges, and the role of adjuvant chemotherapy and radiotherapy after surgical resection remains uncertain.
A multimodal treatment approach including surgical resection, adjuvant chemotherapy, and radiotherapy was well-tolerated in a patient with rare pulmonary artery intimal sarcoma.
Answers are grounded in this paper and cite their sources.
Tolerability shown in one case of pulmonary artery intimal sarcoma; leaves open the role of multimodal therapy pending larger studies.
Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive malignancy originating from the intimal layer of the pulmonary artery with poor prognosis due to its aggressive nature. The management of PAIS poses both diagnostic and therapeutic challenges. It presents with nonspecific symptoms and is often misdiagnosed as pulmonary embolism. While surgical resection is the primary treatment modality, the role of adjuvant chemotherapy and radiotherapy remains uncertain. However, given the high recurrence rate, adjuvant chemotherapy and/or radiotherapy have been utilized in a limited number of case reports. We present the case of a 46-year-old woman who was diagnosed with PAIS and underwent surgical resection followed by adjuvant chemotherapy (ChT) and radiotherapy (RT), demonstrating good tolerance to this multimodal treatment approach.
No takes yet. Share an insight, caveat, or question.
Atahan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: